Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Some factual elements match label content (capsule dosage form; triglyceride indication and cardiovascular risk reduction wording broadly consistent). However, multiple claims are either not supported by the provided prescribing information excerpt (e.g., dosing frequency language, and all manufacturer discount/PAP/generic access/penalties/age-based restriction claims) or are too specific relative to what is shown in the label (e.g., “high triglycerides” context and exact timing language).
Category Scores
Accurate Statements
Vascepa (icosapent ethyl) is a prescription omega-3 fatty acid medication used to treat high triglycerides.
Supported by Indications and Usage: adjunct to diet to reduce TG levels in adult patients with severe (≥500 mg/dL) hypertriglyceridemia; also adjunct to maximally tolerated statin therapy in adult patients with elevated triglyceride (≥150 mg/dL) with additional conditions. (1 INDICATIONS AND USAGE)
Vascepa is available in capsule form.
Supported by Dosage form: capsules (0.5 g and 1 g soft-gelatin capsules) and Dosage and Administration instructions for capsules. (2 DOSAGE AND ADMINISTRATION; and product/dosage form information provided)
Unsupported Statements
Vascepa is used to reduce the risk of heart attack and stroke in patients with high triglycerides and established cardiovascular disease.
Partially reflected in label (risk reduction of cardiovascular events including myocardial infarction and stroke), but the provided excerpt specifies adjunct to statin therapy for adults with elevated TG (≥150 mg/dL) and established cardiovascular disease OR diabetes plus additional risk factors; it does not state the claim exactly as written (“high triglycerides and established cardiovascular disease” without the statin adjunct and specific TG threshold/risk-factor qualifiers). (1 INDICATIONS AND USAGE; 14.1 Prevention of Cardiovascular Events)
Vascepa is typically taken once or twice daily.
Label specifies a daily dose of 4 grams per day taken as four 0.5 g capsules twice daily with food OR two 1 g capsules twice daily with food (i.e., twice daily with food), not “once or twice daily.” (2.2 Dosage and Administration)
Amarin, the manufacturer of Vascepa, offers discounts to eligible patients through its Vascepa Savings Program.
No manufacturer discount/program details are present in the provided FDA label excerpt (Indications, Dosage, Contraindications, Warnings, Adverse Reactions, Interactions, Use in Specific Populations).
The Vascepa Savings Program discounts are only available to patients who meet certain income and eligibility criteria.
Not present in the provided label excerpt.
Vascepa discounts may not be available to patients who have insurance coverage for the medication.
Not present in the provided label excerpt.
Vascepa discounts may require a valid prescription from a healthcare provider.
Not present in the provided label excerpt.
Patients who attempt to obtain Vascepa without a prescription may be subject to penalties or fines.
Not present in the provided label excerpt.
Some Vascepa discounts may be restricted to patients of a certain age or with specific medical conditions.
Not present in the provided label excerpt.
Patients can apply for the Vascepa Savings Program online or through their healthcare provider.
Not present in the provided label excerpt.
Patient assistance programs (PAPs) offer discounts or free medication to eligible patients.
General PAP claim is not supported by the provided label excerpt; no PAP details are included.
Patients may be able to access generic or biosimilar versions of Vascepa.
No information about generics/biosimilars is included in the provided label excerpt.
Contradictions
Important Omissions
For the cardiovascular risk reduction indication, the claim should reflect that Vascepa is indicated as an adjunct to maximally tolerated statin therapy and includes specified patient criteria (elevated TG ≥150 mg/dL and established CVD OR diabetes plus ≥2 additional risk factors).
Importance:
Moderate
The label-specific limitation of use regarding pancreatitis risk in severe hypertriglyceridemia is not mentioned (e.g., “effect ... on the risk for pancreatitis ... has not been determined”).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Most safety-critical label content (contraindications/warnings/interactions) was not claimed. However, the dosing-frequency claim (“once or twice daily”) conflicts with the label’s specified twice-daily regimen, which could cause dosing inaccuracies if relied upon.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Partially Aligned
Primary Issue
Several claims are not supported by the provided FDA label excerpt, especially all discount/PAP/generic/penalties program details; additionally, the dosing frequency claim is inconsistent with the label.
Suggested Improvement
Limit claims to label-supported content: (1) specify indicated populations and adjunct-to-statin/diet qualifiers as written; (2) state dosing exactly as 4 g/day taken as twice-daily capsules with food (either 0.5 g x4 BID or 1 g x2 BID) and swallow whole; (3) remove manufacturer program, eligibility/insurance/age restriction, online application, penalties, PAP, and generic/biosimilar availability claims unless supported in the provided prescribing information.